Dr. Sergio Giralt, MD – New York, NY | Oncology
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. - Abstract - Europe PMC
Dr. Eytan M. Stein, MD | New York, NY | Oncologist | US News Doctors
Guidelines for Cord Blood Unit Thaw and Infusion
Division of Hematologic Malignancies: Our Faculty | Memorial Sloan Kettering Cancer Center
Correlation between bank prefreeze and MSKCC postthaw total CD34 1 cell... | Download Scientific Diagram
Division of Hematologic Malignancies: Our Faculty | Memorial Sloan Kettering Cancer Center
JCI - Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
Politikos, Ioannis
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for
Ioannis Politikos (@ipolitikos) / Twitter
Division of Hematologic Malignancies: Our Faculty | Memorial Sloan Kettering Cancer Center
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation | NEJM
Minutes
Evaluation of Cord Blood Total Nucleated and CD34<sup>+</sup> Cell Content, Cell Dose, and 8-Allele HLA Match by Patient Ancestry. - Abstract - Europe PMC
Ioannis Politikos (@ipolitikos) / Twitter
Gunjan SHAH | Assistant Attending | Memorial Sloan Kettering Cancer Center, New York City | MSKCC | Bone Marrow Transplant Service
Ioannis Politikos (@ipolitikos) / Twitter
Times, Locations & Directions for Dr. Nathan Teich
Ioannis Politikos (@ipolitikos) / Twitter
JCI - Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
Ioannis Politikos - Assistant Member, Adult BMT Service - Memorial Sloan Kettering Cancer Center | LinkedIn
Ioannis Politikos | Memorial Sloan Kettering Cancer Center
Dr. Anita Sultan Hematology/Oncology. Springfield NJ
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
Open Label Phase II Study of Ixazomib for the Prevention of Recurrent or Late Acute and Chronic Graft-versus-Host Disease at 1-y
